Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C.-H. Yun

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research

Cancer Research

Oncology

2015

English

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Clinical Cancer Research

Cancer Research

Oncology

2011

English

Related publications

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations

Journal of Thoracic Disease

Pulmonary

Respiratory Medicine

2017

English

AXL/epidermal Growth Factor Receptor (EGFR) Complexes in Breast Cancer - Culprits for Resistance to EGFR Inhibitors?

Breast Cancer Research

Cancer Research

Oncology

2013

English

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

Journal of Thoracic Oncology

English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics

Cancer Research

Oncology

2019

English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia

English

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C.-H. Yun

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Related publications

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations

AXL/epidermal Growth Factor Receptor (EGFR) Complexes in Breast Cancer - Culprits for Resistance to EGFR Inhibitors?

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer